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Rationale: Pulmonary hypertension (PH) commonly complicates the course of patients with id-
iopathic pulmonary fibrosis (IPF). It has a significant impact on outcomes and is, therefore, im-
portant to detect.
Objectives: We sought to characterize the accuracy and performance characteristics of the
right ventricular systolic pressure (RVSP) as estimated by echocardiography (ECHO) alone
and in conjunction with physiologic indices in predicting the presence of PH in IPF patients.
Methods: Cross-sectional study of IPF patients from two large tertiary centers in whom both
ECHO and right-heart catheterization (RHC) were available.
Measurements and main results: There were 110 patients with available ECHOs and RHCs.
Estimates of RVSP were reported in 60 of these patients (54.5%) of whom 22 (36.6%) had PH,
while 16 of the 50 patients without RVSP estimate (32%) had PH. Twenty-four of 60 (40%) ECHOs
accurately reflected the pulmonary arterial systolic pressure as measured by RHC. An optimality for Carbon Monoxide; DLCO%, Diffusing Capacity for Carbon Monoxide Percent Predicted; ECHO,
Capacity; FVC%, Forced Vital Capacity Percent Predicted; IPF, Idiopathic Pulmonary Fibrosis; mPAP,
, Pulmonary Artery Pressure; PASPcath, Pulmonary Artery Systolic Pressure obtained via right-heart
ction Tests; PH, Pulmonary Hypertension; RHC, Right-Heart Catheterization; RVSPecho, Right Ventric-
y echocardiography; 6MWT, The six-minute walk test; 6MWD, The 6-minute walk test distance;
air at rest; RAsatexercise, Room air oxygen saturation with exercise.
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1306 S.D. Nathan et al.RVSP threshold for the screening of PH could not be detected. When assessed in combination
with various thresholds of PFT and 6-minute walk test (6MWT) parameters, the performance
characteristics of the RVSP were slightly improved.
Conclusion: The RVSP is not an accurate test for the assessment of PH in IPF patients. Aware-
ness of the various combinations of threshold values for RVSP with and without PFT and 6MWT
might nonetheless assist clinicians in risk stratifying IPF patients for the presence of PH.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
IPF is a disease that carries with it a poor prognosis with an
estimated survival of 2.5e5 years.1e3 There are multiple
factors that impact on the prognosis and clinical course of
patients with this disease. One such factor is the develop-
ment of pulmonary hypertension (PH).4,5 This can occur
at any stage during the course of the disease and has
been shown to impact patients’ functional status as well
as outcomes. For this reason, it appears to be an important
clinical measure to assess for.
The gold standard for the measurement of PH is right
heart catheterization (RHC), but this is invasive with the
inherent risk of complications. As yet, no non-invasive
measurement has been shown to suffice as an adequate
screening or diagnostic tool for the presence of PH in IPF.6
Echocardiography (ECHO) has been touted as providing an
accurate measurement of the right ventricular systolic
pressure (RVSPecho) based on the estimated flow of the tri-
cuspid regurgitant jet.7e9 We sought to evaluate the utility
of the RVSPecho as a surrogate for the Pulmonary Artery
Systolic Pressure (PASPcath) obtained by RHC in a cohort of
patients with IPF.
Methods
We performed a retrospective cross-sectional study of IPF
patients, diagnosed as per the ATS/ERS criteria,10 from two
large tertiary centers. All patients evaluated from 1996 to
2006 qualified for the analysis if they had an ECHO and
RHC performed as part of their evaluation. Some but not
all of the patients were seen and evaluated as part of
a transplant work-up. Contemporaneous pulmonary func-
tion tests were also recorded. The ECHO reports were scru-
tinized and patients were then stratified as to whether or
not there was a RVSPecho reported by the echocardiog-
raphers. For the group in whom there was a RVSPecho, this
number was recorded and then correlated to the PASPcath.
RVSPecho was estimated using standard techniques.
7e9 Spe-
cifically, the peak pressure gradient between the right
ventricle and atrium during systole was calculated using
the modified Bernoulli’s equation, while the right atrial
pressure was estimated from the degree of inspiratory col-
lapse of the inferior vena cava. These were then summed to
provide an estimate of the RVSPecho.
The accuracy of the RVSPecho in relation to the PASPcath
was assessed. Accuracy was arbitrarily defined as a RVSPecho
within 10 mmHg of the PASPcath. A further analysis was
undertaken to assess whether the severity of disease based
on the FVC% predicted and DLCO% predicted, affected theaccuracy of this measure. A similar analysis was performed
to assess if the severity of PH influenced the accuracy.
The performance characteristics of various incremental
threshold values of the RVSP as a predictor of PH were
assessed. We defined PH as resting mean pulmonary artery
pressure (mPAP) from RHC of >25 mmHg. We further sought
to determine whether a combination of PFT or 6-minute
walk test (6MWT) data could improve the predictive value
of the RVSPecho. In this regard, we assessed the perfor-
mance characteristics of different values of the RVSPecho
in conjunction with different thresholds of the following:
the FVC% predicted, the DLCO% predicted, the ratio of the
FVC% to DLCO% predicted, the resting room air oxygen satu-
ration obtained via pulse oximetry (RAsatrest), the room air
oxygen saturation nadir with exercise (RAsatexercise) and the
6MWT distance (6MWD). All 6MWTs were performed as per
the ATS standard and only those that were performed on
room air were included in the analysis.11
Statistical methods
Continuous data are presented as mean standard devia-
tion (SD). Categorical data are presented as frequency
and percent. Student’s t-test, Pearson correlation coeffi-
cients and Chi-square tests were used to determine statis-
tical significance where appropriate. P-values 0.05 were
considered statistically significant. Estimates of positive
and negative predictive values were calculated using
Bayes’ Theorem with an estimated PH background preva-
lence set at 34.5%. All analyses were conducted in SAS
(Version 9, Cary, NC).
Results
There were 110 patients who qualified for the analysis over
a 10-year period (1996e2006). All of the patients fulfilled
the ATS/ERS guidelines for the diagnosis of IPF; of these
60.9% had the diagnosis confirmed by surgical lung biopsy.
Although all these patients had ECHOs performed, RVSPecho
was reported in only 60 of the patients (54.5%). Demo-
graphic, PFT and 6MWT data of the patient cohort are
shown in Table 1. Most of these patients had advanced
disease as evidenced by their PFTs, but there were some
who had more ‘‘mildemoderate’’ disease, with 15/60
(25%) having FVCs> 60% predicted. There was no discern-
able demographic or disease severity difference between
this final cohort and the group in whom there was no
RVSPecho reported. As per the International Society for
Heart and Lung Transplantation guidelines, the majority
of these patients were also potential transplant candidates,
Table 1 Demographics of the patient cohort (nZ 60)
Male, n (%) 33 (55.0%)
Age, mean SD 62.9 8.6
aFVC% 50.6 14.8
aFEV1% 58.5 16.5
bDLCO% 29.6 34.4
mPAP 24.9 9.2
c6MWD 242.4 171.7
FVC%Z forced vital capacity percent predicted; FEV1%Z
forces expired volume in the first one second percent pre-
dicted; DLCO%Z diffusing capacity for carbon monoxide
percent predicted; mPAPZmean pulmonary artery pressure;
and 6MWDZ 6-minute walk test distance.
a FVC% and FEV1% data available in 58 patients.
b DLCO% data available in 36 patients.
c Twenty-eight patients completed 6MWT on room air.
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Figure 2 Accuracy of the RVSPecho compared to the PASPcath
pressure as measured by right-heart catheterization in relation
to the mean PAP.
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Role of echo in detecting PH in IPF 1307specifically 33/60 were <65 years of age.12 Of the 60
patients, 22 (36.6%) had PH, while 16 of the 50 patients
without ECHO estimates (32%) had PH. The mean time
between the RHC and ECHO was 32 78 days while the
mean difference between the RVSPecho and PASPcath from
RHC was 8 14.2 mmHg.
Twenty-four of 60 (40%) ECHOs accurately reflected the
PASPcath using the definition of accuracy as a RVSP to PASPcath
difference of 10 mmHg. RVSPecho overestimated the
PASPcath in 29/60 (48.3%) cases, while it underestimated
the PASPcath in 7/60 (11.6%). In 15 of the cases, the time
interval between the two studies was 1 and 3 months, while
in the remaining 13 cases it was beyond 3 months. The lon-
gest time interval between the two studies in any patient
was 7.5 months. In 51/60 cases, the ECHO was obtained con-
currently or before the RHC. In 32 of the cases, the ECHOs
were within 1 month of the RHC. In this group, the mean dif-
ference between the RVSPecho and PASPcath was also
8 12.3 mmHg. Only 37.5% (12/32) of these cases fell within
the range of accuracy.
There was no correlation between the severity of IPF
based on the FVC% and the DLCO% predicted and the degree
of accuracy in the RVSPecho estimate. The FVC% predicted to
RVSPePAS PASPcath difference is depicted in Fig. 1. Similarly,
there did not appear to be a relationship between the RHC-
measured mPAP and the accuracy of the RVSPecho (Fig. 2).10 20 30 40 50 60 70 80 90 100-40
-30
-20
-10
0
10
20
30
40
r = -0.03
FVC%
R
V
S
P
-
P
A
S
 
(
m
m
H
g
)
Figure 1 Accuracy of the RVSPecho compared to the PAScath
pressure as measured by right-heart catheterization in relation
to the FVC% predicted.The performance characteristics of RVSPecho as a diag-
nostic tool for PH are depicted in Fig. 3. As expected, the
lower the threshold RVSPecho value, the greater the sensi-
tivity. The specificity increases with the threshold value,
but does so at the expense of the sensitivity.
The PFT parameters that had the best performance
characteristics for predicting PH when used in conjunction
with the RVSPecho were first the DLCO% predicted, then the
FVC/DLCO% ratio and lastly, the FVC% predicted. In general,
the higher the RVSPecho and the lower the DLCO are, the
greater is the likelihood that the patient has PH (Table 2).
Similarly, the higher the FVC/DLCO% ratio and the higher
the RVSPecho, the greater the likelihood of PH.0
1007550250
False Positive
RVSPecho (mmHg) SpecificitySensitivity
RVSPecho > 30 64.834.413.2 (3.3-30.9)86.4 (69.8-95.0)
RVSPecho > 35 80.139.028.9 (14.1-47.8)86.4 (69.8-95.0)
RVSPecho > 40 75.740.944.7 (26.7-63.0)72.7 (51.6-87.1)
RVSPecho > 45 70.939.652.6 (33.5-69.8)59.1 (38.7-76.8)
RVSPecho > 50 72.045.568.4 (48.3-82.9)50.0 (30.7-69.3)
RVSPecho > 55 73.057.784.2 (60.4-91.6)40.9 (23.2-61.3)
RVSPecho > 60 70.664.592.1 (73.9-98.9)27.3 (12.9-48.4)
Positive
Predictive
Value 
Negative
Predictive
Value
Diagnostic and 95% CI
Figure 3 Diagnostic accuracy of incremental thresholds of
the RVSPecho for the detection of PH in IPF depicted as
a receiver operator characteristic curve.
Table 2 Performance characteristics of PFTs and six-minute walk data alone and in combination with the RVSPecho for the
detection of pulmonary hypertension
RVSPecho excluded
a
RVSPecho (mmHg)
>30 >40 >50 >60
DLCO% <30 62.5/66.7 36.8/78.9 30.0/86.0 25.0/91.5 17.4/98.0
<40 87.5/23.1 66.7/46.7 52.6/68.6 31.6/82.1 18.2/97.6
<50 95.8/10.3 77.8/32.1 63.2/63.6 36.8/81.1 22.7/97.4
RAsatrest <95 90.9/50.0 63.6/57.1 54.5/60.7 36.4/78.6 18.2/100
<90 9.1/88.9 5.9/93.0 5.9/93.0 5.9/100 5.9/100
RAsatexercise <85 100/61.9 45.5/83.3 41.7/89.5 23.1/94.7 14.3/97.6
<80 56.1/72.2 8.3/97.4 7.7/100 7.1/100 6.7/100
6MW Distance (meters) <100 53.3/88.9 28.6/97.1 25.0/97.6 16.7/97.8 9.5/98.0
<200 80.0/61.1 53.8/80.0 40.0/86.5 17.6/97.6 10.0/97.9
<300 86.7/52.8 61.5/75.0 46.7/82.9 23.5/94.9 10.0/97.9
Data represent the sensitivity and specificity (est. PH prevalence of 34.5%).
RVSPecho e Right Ventricular Systolic Pressure as estimated by echocardiography; 6MWD e The 6-minute walk test distance; RAsatrest e
Oxygen saturation on room air at rest; and RAsatexercise e Room air oxygen saturation with exercise.
a RVSPecho excludedZ the physiologic parameters alone as predictors of PH in the patient population in whom there was an RVSPecho
reported.
1308 S.D. Nathan et al.The parameter from the 6MWT that best predicted PH
was exercise desaturation; specifically, desaturation to
<85% had a 100% sensitivity and a 61.9% specificity for
associated PH. ECHO RVSP improved the specificity of
exercise desaturation, but this compromised the sensitiv-
ity. For example, desaturation to <85% during the 6MWT in
conjunction with a RVSPecho> 40 mmHG increased the
specificity to 89.5%, but with an associated sensitivity of
only 41.7%. Lower thresholds for RAsatrest in the context
of higher RVSPecho also had high specificities for underlying
PH; for example, oxygen saturation <90% at rest in con-
junction with a RVSPecho> 50 mmHg had specificity for PH
of 96.9% (Table 2). The greatest value of using the tests
in combination appears to be the high positive predictive
values (PPV) seen with various combinations of ECHO and
resting and/or exercise oxygen saturation.Discussion
Pulmonary Hypertension frequently complicates the course
of IPF patients and is associated with a worse survival.4,5
Recognition of PH is important in determining prognosis
and the timing of listing for lung transplantation. RHC
remains the gold standard test for the assessment of PH.
At this time, the importance of detecting PH as a target
of therapy remains uncertain.13,14 RHC is expensive, time-
consuming, invasive and impractical to assess in serial
fashion. Therefore, a non-invasive diagnostic tool would
be very helpful in the evaluation of IPF patients to enable
the appropriate timing of RHC.
We describe the first comprehensive analysis of the
RVSPecho as a screening tool for PH in a well-characterized
population of patients with IPF, diagnosed as per the ATS/
ERS guidelines. Based on the results of our study, RVSPecho
does not perform with sufficient accuracy to be relied
upon as a stand-alone test for PH in IPF. These findingsare in keeping with those of Arcasoy and associates, who
described similar inaccuracies in patients with various
forms of advanced lung disease referred for transplanta-
tion.14,15 In their interstitial lung disease (ILD) subgroup
(nZ 106), they reported an accuracy rate of 48% compared
to our 40% using the same definition. Further, utilizing
a threshold RVSPecho> 45 mmHg as a predictor for the pres-
ence of PH, they reported a sensitivity, specificity, PPV and
negative predictive value of 85%, 17%, 60% and 44%, respec-
tively. However, their patient subgroup with ILD included
connective tissue disease patients (with and without pul-
monary vascular disease), various pneumoconioses as well
as diverse idiopathic interstitial pneumonias, whereas we
restricted our cohort to well-defined IPF patients. Further,
we have expanded on their observations by reporting the
performance characteristics of various threshold values of
the RVSPecho as a predictor of PH alone and in combination
with PFT and 6MWT data.
Nearly one-third of patients in whom there was no
RVSPecho reported had PH by RHC. Therefore, although the
sensitivity of ECHO was higher utilizing low threshold values
for the RVSPecho, this cannot be relied upon as a screening
tool for underlying PH. Further, this high sensitivity was asso-
ciated with an unacceptably low specificity. For example,
using an estimated RVSPecho> 35 mmHg as a predictor of
PH yielded a sensitivity of 86.4%, but a specificity of only
28.9% (Table 2). On the other end of the spectrum, a high
RVSPecho has very good specificity, but lacks sufficient sensi-
tivity. This too is of limited clinical value, but does allow
reasonable certainty as to the presence of PH.
We then assessed the performance characteristics of
RVSPecho in relation to patients’ PFTs and 6MWT data to as-
sess if a step-wise approach incorporating two independent
diagnostic tests, would improve the accuracy of detection.
We have previously shown that the presence of underlying
PH does not correlate with lung volumes but does have an
association with a low DLCO.
16,17 As shown in Table 2, we
Role of echo in detecting PH in IPF 1309assessed whether lower levels of the RVSPecho could yield
similar high sensitivities, but with greater specificities
when assessed in conjunction with patients’ PFTs or
6MWT data. Although the specificity was increased with
this approach, it was at the expense of the sensitivity.
For example, the sensitivity of a RVSPecho> 30 mmHg de-
creased from 86.4% to 66.7% when it was evaluated in con-
junction with a DLCO< 40% predicted (Table 2). The value
of this combined approach was realized with the specificity,
where lower threshold levels for the RVSPecho yielded high
values when assessed in conjunction with PFT or 6MWT
data. For example, a RVSPecho> 30 mmHg in conjunction
with a DLCO< 30%, resulted in a specificity of 78.9%. This is
in comparison to specificities of 13.2% and 66.7% for each
of these variables alone. RVSPecho did not add much to the
predictive abilities of 6MWT parameters, which by them-
selves have good performance characteristics for the detec-
tion of PH. For example, desaturation to<85% while on room
air during the walk test was associated with a sensitivity and
specificity for PH of 100% and 61.9%, respectively.
There are certain limitations to our study. Although
RVSPecho was estimated using standard methodology at both
institutions, the estimations were collated from multiple
technicians and interpreters potentially increasing the
variability of the measurements. This, however, is also
a strength of the study as it is more reflective of the circum-
stances in clinical practice. ECHOs were not performed con-
currently with RHCs but we do not believe that this
impacted our findings. Although there can be serial change
in PA pressures in patients with IPF, these are likely to be
more significant towards the later stages of the disease.18
In addition, our analysis of the subgroup with ECHOs and
RHCs within a 1-month timeframe was very similar to the
group as a whole. Further in 51/60 cases, the ECHO was
performed concurrently or prior to the RHC. Most of the
cases of inaccuracy were due to ECHO overestimating the
PASPcath. Since pressures are unlikely to decrease with
time, this, therefore, lends further support to the inaccur-
acy of ECHO. The measurements of the RVSPecho were re-
ported in only 55% of the patients. There are likely
multiple reasons for this including the absence of a tricuspid
regurgitant jet, or the technician not looking for or unable
to identify a jet. Rather than being a limitation of our
study, this is a limitation of ECHO and/or the experience,
methodology and tenacity of the technicians in detecting
and accurately assessing the peak velocity of the regurgi-
tant jet. One of the important messages of our analysis is
that the lack of a reported RVSPecho does not infer the ab-
sence of PH, since about one-third of these patients did in-
deed have PH as measured by RHC. Also, other ancillary
ECHO features of right ventricular function, such as the tri-
cuspid annular plane systolic excursion, which might have
indicated the possible presence of PH were not routinely
assessed for.18,19 Use of Doppler ultrasound flow assessment
of the internal jugular vein has also been proposed as a in-
direct measure of the mPAP.20 Lastly, the patients who un-
derwent both ECHO and RHC were generally a sicker, but
robust subgroup of patients and whether our data can be
extrapolated to all IPF patients will require further study.
In conclusion, our study demonstrates that RVSPecho
might not be an accurate tool for the assessment of PH in
IPF. Even when used in conjunction with standard PFTmeasures and 6MWT data, we were unable to define the op-
timal combination of parameters to provide sufficient accu-
racy to diagnose PH in IPF. However, our study does provide
valuable information, especially, with regards to the high
specificity for PH with the various combinations of parame-
ters. When assessed in conjunction with PFTs or 6MWT
data, lower threshold values of the RVSP do perform with
sufficient specificity to implicate the likely presence of as-
sociated PH. Awareness of the performance characteristics
of RVSPecho with and without PFTs and 6MWT data might
enable the optimal timing of RHC in selected patients. A
non-invasive tool that provides both a high sensitivity and
specificity for PH in IPF remains to be identified and vali-
dated. The measurement of brain natriuretic peptide might
have a role in this regard, but remains to be validated.21,22
The final determination of the role of ECHO in assessing
for PH in IPF will require a prospective study, inclusive
of a broader range of disease severity, with experienced
echocardiographers focusing on the right side of the heart.
Until such time, RHC remains the gold standard test for PH
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